Target Price | $117.30 |
Price | $99.51 |
Potential | 17.88% |
Number of Estimates | 33 |
33 Analysts have issued a price target Lam Research 2026 . The average Lam Research target price is $117.30. This is 17.88% higher than the current stock price. The highest price target is $141.75 42.45% , the lowest is $75.75 23.88% . | |
A rating was issued by 39 analysts: 30 Analysts recommend Lam Research to buy, 9 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Lam Research stock has an average upside potential 2026 of 17.88% . Most analysts recommend the Lam Research stock at Purchase. |
35 Analysts have issued a sales forecast Lam Research 2026 . The average Lam Research sales estimate is $19.1b . This is 3.84% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $21.2b 14.95% , the lowest is $17.2b 6.89% .
This results in the following potential growth metrics:
2025 | $18.4b | 23.68% |
---|---|---|
2026 | $19.1b | 3.84% |
2027 | $21.5b | 12.23% |
2028 | $22.6b | 5.18% |
2029 | $24.8b | 9.93% |
21 Analysts have issued an Lam Research EBITDA forecast 2026. The average Lam Research EBITDA estimate is $6.8b . This is 8.12% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $7.5b 19.59% , the lowest is $5.2b 16.99% .
This results in the following potential growth metrics and future EBITDA Margins:
2025 | $6.3b | 34.19% |
---|---|---|
2026 | $6.8b | 8.12% |
2027 | $7.7b | 13.18% |
2028 | $8.9b | 15.04% |
2029 | $8.7b | 1.24% |
2025 | 34.10% | 8.50% |
---|---|---|
2026 | 35.51% | 4.12% |
2027 | 35.81% | 0.84% |
2028 | 39.16% | 9.35% |
2029 | 35.18% | 10.16% |
35 Lam Research Analysts have issued a net profit forecast 2026. The average Lam Research net profit estimate is $5.2b . This is 2.08% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $6.2b 15.61% , the lowest is $4.3b 19.02% .
This results in the following potential growth metrics and future Net Margins:
2025 | $5.4b | 39.98% |
---|---|---|
2026 | $5.2b | 2.08% |
2027 | $6.2b | 18.36% |
2028 | $6.8b | 9.41% |
2029 | $7.8b | 14.10% |
2025 | 29.06% | 13.18% |
---|---|---|
2026 | 27.41% | 5.69% |
2027 | 28.90% | 5.44% |
2028 | 30.06% | 4.01% |
2029 | 31.20% | 3.79% |
35 Analysts have issued a Lam Research forecast for earnings per share. The average Lam Research EPS is $4.14 . This is 1.19% lower than earnings per share in the financial year 2025. The highest EPS forecast is $4.88 16.47% , the lowest is $3.42 18.38% .
This results in the following potential growth metrics and future valuations:
2025 | $4.15 | 43.10% |
---|---|---|
2026 | $4.14 | 0.24% |
2027 | $4.89 | 18.12% |
2028 | $5.36 | 9.61% |
2029 | $6.11 | 13.99% |
Current | 25.63 | 8.01% |
---|---|---|
2026 | 25.97 | 1.34% |
2027 | 21.94 | 15.52% |
2028 | 20.05 | 8.61% |
2029 | 17.58 | 12.32% |
Based on analysts' sales estimates for 2026, the Lam Research stock is valued at an EV/Sales of 7.00 and an P/S ratio of 7.10 .
This results in the following potential growth metrics and future valuations:
Current | 7.27 | 3.71% |
---|---|---|
2026 | 7.00 | 3.72% |
2027 | 6.24 | 10.90% |
2028 | 5.93 | 4.93% |
2029 | 5.39 | 9.04% |
Current | 7.37 | 4.32% |
---|---|---|
2026 | 7.10 | 3.70% |
2027 | 6.33 | 10.90% |
2028 | 6.01 | 4.93% |
2029 | 5.47 | 9.04% |
Analyst | Rating | Action | Date |
---|---|---|---|
Argus Research |
Buy
➜
Buy
|
Unchanged | Aug 01 2025 |
Citigroup |
Buy
➜
Buy
|
Unchanged | Aug 01 2025 |
Mizuho |
Outperform
➜
Outperform
|
Unchanged | Aug 01 2025 |
Raymond James |
Outperform
➜
Outperform
|
Unchanged | Jul 31 2025 |
Oppenheimer |
Outperform
➜
Outperform
|
Unchanged | Jul 31 2025 |
Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Jul 31 2025 |
Needham |
Buy
➜
Buy
|
Unchanged | Jul 31 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Argus Research:
Buy
➜
Buy
|
Aug 01 2025 |
Unchanged
Citigroup:
Buy
➜
Buy
|
Aug 01 2025 |
Unchanged
Mizuho:
Outperform
➜
Outperform
|
Aug 01 2025 |
Unchanged
Raymond James:
Outperform
➜
Outperform
|
Jul 31 2025 |
Unchanged
Oppenheimer:
Outperform
➜
Outperform
|
Jul 31 2025 |
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Jul 31 2025 |
Unchanged
Needham:
Buy
➜
Buy
|
Jul 31 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.